Research programme: cell cycle protein inhibitors - SRI International
Alternative Names: SR 13179; SR 13654; SR 13677Latest Information Update: 16 Jul 2016
At a glance
- Originator SRI International
- Class Catechins
- Mechanism of Action Angiogenesis inhibitors; BIRC5 protein inhibitors; Cell cycle protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Prostate-cancer in USA (PO)
- 13 Oct 2009 Early research in Prostate cancer in USA (PO)